EUVIMEDEUVIMED entdecken
Crossref

Mesna, Doxorubicin, Ifosfamide and Dacarbazine (MAID) Combination Chemotherapy for Retroperitoneal Sarcoma: A Single-center Experience

Yudai Ishiyama, Toru Inakawa, Maki Yoshino, Koichi Nishimura, Toshihide Horiuchi, Hiroki Ishihara, Daisuke Toki, Tsunenori Kondo

Anticancer Research · 2024

DOI: 10.21873/anticanres.17137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Yudai Ishiyama und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Ifosfamide, Doxorubicin, Antineoplastic Combined Chemotherapy Protocols, Retroperitoneal Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: There is limited evidence regarding the systemic treatment of retroperitoneal soft-tissue sarcoma, and the current Japanese guidelines fail to make definitive suggestions. Here, we report our experience with combination chemotherapy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in this population. PATIENTS AND METHODS: We retrospectively reviewed the records of eight patients (three male and five female) who received MAID for pathologically diagnosed metastatic unresectable retroperitoneal sarcoma (either leiomyosarcoma or pleomorphic sarcoma) between October 2019 and January 2022. Treatment efficacy, tolerability (need for dose reduction), and safety profiles were evaluated and summarized. RESULTS: At initiation, the median age was 56.0 years, and the body mass index was 20.0 kg/cm2 Six patients had Eastern Cooperative Oncology Group performance status scores of 0. The net clinical benefit was a partial response in three (37.5%) patients, stable disease in four (50.0%), and progressive disease in one (12.5%). During the median 90.8 weeks of follow-up, disease in five patients progressed, resulting in a median progression-free survival of 48.4 weeks, and five deaths occurred, resulting in an overall survival of 95.1 weeks. Commonly observed adverse events were neutropenia (eight patients), anemia (eight patients), and decreased platelet count (seven patients), which led to dose reduction (60-80%) in six patients. CONCLUSION: MAID combination therapy may be an acceptable option for advanced retroperitoneal sarcoma; however, its benefits must be carefully assessed owing to its not insignificant toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IfosfamideDoxorubicinAntineoplastic Combined Chemotherapy ProtocolsRetroperitoneal NeoplasmsSarcomaMesnaDacarbazineHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdult

Stichwörter der Autor:innen

Doxorubicinmultimodal therapyretroperitonealsarcoma

Substanzen

IfosfamideDoxorubicinMesnaDacarbazine

Autor:innen und Institutionen

  • Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
  • Department of Urology and Transplant Surgery, Toda Chuo General Hospital, Saitama, Japan.
  • Department of Urology and Transplant Surgery, Toda Chuo General Hospital, Saitama, Japan kondo.tsunenori@twmu.ac.jp.

Zitieren

APA

Ishiyama, Y., Inakawa, T., Yoshino, M., Nishimura, K., Horiuchi, T., Ishihara, H., Toki, D., & Kondo, T. (2024). Mesna, Doxorubicin, Ifosfamide and Dacarbazine (MAID) Combination Chemotherapy for Retroperitoneal Sarcoma: A Single-center Experience. Anticancer Research. https://doi.org/10.21873/anticanres.17137

Vancouver

Ishiyama Y, Inakawa T, Yoshino M, Nishimura K, Horiuchi T, Ishihara H, et al. Mesna, Doxorubicin, Ifosfamide and Dacarbazine (MAID) Combination Chemotherapy for Retroperitoneal Sarcoma: A Single-center Experience. Anticancer Research. 2024. doi:10.21873/anticanres.17137

BibTeX
@article{Ishiyama2024,
  author = {Ishiyama, Yudai and Inakawa, Toru and Yoshino, Maki and Nishimura, Koichi and Horiuchi, Toshihide and Ishihara, Hiroki and Toki, Daisuke and Kondo, Tsunenori},
  title = {Mesna, Doxorubicin, Ifosfamide and Dacarbazine (MAID) Combination Chemotherapy for Retroperitoneal Sarcoma: A Single-center Experience},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17137}
}
Kostenlos starten →